Cancer Network Staff

The ctDNA testing guidance in the updated NCCN guidelines were narrowly defined by the IMvigor011 trial population, according to Mamta Parikh, MD, MS.

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

The FDA granted breakthrough therapy designation to olomorasib for previously treated, KRAS G12C-mutant advanced pancreatic cancer.

In a real-world CASCADE database analysis, prophylactic cranial irradiation was associated with a median overall survival of 29.8 months in limited-stage SCLC.

A novel alternative-salt capsule formulation of cabozantinib has received FDA tentative approval for advanced renal cell carcinoma, hepatocellular carcinoma, and neuroendocrine tumors.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Gedatolisib plus fulvestrant, with or without palbociclib, now holds NCCN Category 1 status for HR+/HER2– PIK3CA wild-type advanced breast cancer.

María Teresa Bourlon, MD, MSc, MS, discussed key kidney abstracts from the 2026 ASCO Meeting, including the LenCabo trial, the RAMPART trial, and the RADICAL trial.

The regulatory decision for subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell carcinoma was based on phase 1b/2 OrigAMI-4 data.

Selinexor maintenance therapy did not significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in a phase 3 trial.

Frank McCormick, PhD, FRS, DSc (Hon), discussed his vision for preemptively treating KRAS-driven precancerous lesions, differences between KRAS allele subtypes, and where the field is headed over the next decade.

The UAE granted marketing authorization for nogapendekin alfa plus BCG in BCG-unresponsive NMIBC and with checkpoint inhibitors in metastatic NSCLC.

Data from a phase 1 trial validate FcRH5 as a “good target” in multiple myeloma therapy, according to Adam D. Cohen, MD.

Adding mFOLFOX6 and bevacizumab to atezolizumab cut the risk of progression or death by 58% vs atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer.

Cema-cel received RMAT and fast track designations for first-line consolidation therapy in MRD-positive large B-cell lymphoma based on phase 2 ALPHA3 data.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.

Data from a first-in-human phase 1 trial assessing ISM6331 in mesothelioma and other solid tumors will be presented at the ESMO Congress 2026.

Key genitourinary oncology updates emerged from ASCO 2026, focusing on balancing efficacy and AEs.

Final phase 3 BOND-003 Cohort C results showed a 75.5% complete response rate with cretostimogene grenadenorepvec in BCG-unresponsive NMIBC.

Risvutatug rezetecan improved progression-free survival in the phase 3 ARTEMIS-011 trial for patients with relapsed osteosarcoma.

No adverse effects or injuries associated with the presence of particulate matter in 3 lots of injectable cyclophosphamide have been reported to date.

As the FDA's ODAC prepares to weigh in ahead of an August 2, 2026, decision date, take a look at RP1's clinical trial and regulatory journey.

Sonesitatug vedotin met dual primary survival end points in the phase 3 CLARITY-Gastric01 trial in CLDN18.2-positive gastric/GEJ cancer.

Health-related quality of life was comparable between belzutifan plus lenvatinib and cabozantinib among those with previously treated renal cell carcinoma.

In a phase 3 trial, ensartinib raised the 24-month disease-free survival rate to 86.4% vs 53.5% with placebo in patients with resected ALK-positive NSCLC.

"I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.

A multidisciplinary panel discussed second-line CAR T-cell candidacy, real-world referral barriers, and the management of delayed toxicities in DLBCL.

Among evaluable patients with B-cell NHL from the dose-escalation portion of the trial without CNS involvement, all CRs were sustained through 6 months.

Based on phase 2 data, adding consolidative thoracic radiation cannot be recommended outside of clinical trials for unselected patients with ES-SCLC.

Nikesh Shah, MD, discussed the specific factors that shape the choice between a bispecific and CAR T-cell therapy in follicular lymphoma.